TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06083831

Intervention type: OTHER
Intervention: feeding type
Description: In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.

Intervention type: OTHER
Intervention: feeding type
Description: In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
Study: NCT01852682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study: NCT05844371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirelizumab
Description: Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy with oxaliplatin + heroda
Description: chemotherapy with oxaliplatin + heroda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with oxaliplatin + heroda
Description: chemotherapy with oxaliplatin + heroda
Study: NCT05773950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.
Study: NCT05314764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
Study: NCT04779190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Gallium-aluminum-arsenide diode laser device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Therapeutic pulsed ultrasound with a frequency of 1 MHz

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise
Description: Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
Study: NCT06179329

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass graft
Description: Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass graft
Description: Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
Study: NCT05802394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Later-line therapy
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study: NCT06239298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: intravenous infusion(IV), once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: intravenous infusion(IV), once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Study: NCT04964570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video _ behavioral change module
Description: A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video _ behavioral change module
Description: A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support.
Study: NCT04669288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging.
Study: NCT06014242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral vascular flow reserve measurement
Description: Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
Study: NCT06155604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: Standard maintenance therapy
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard maintenance therapy
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
Study: NCT05090995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Management and Feedback
Description: Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Self-Management
Description: Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
Study: NCT05905575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family dyad diabetes intervention
Description: The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
Study: NCT05204329

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC Secretome Eye Drops
Description: MSC Secretome eye drop will be dispensed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC Secretome Eye Drops
Description: MSC Secretome eye drop will be dispensed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC Secretome Eye Drops
Description: MSC Secretome eye drop will be dispensed.
Study: NCT04817384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
Study: NCT05539833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSH01 injection
Description: TCR-T cell injection
Study: NCT04818424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft exosuit
Description: A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without exosuits
Description: Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
Study: NCT05031988

Intervention type: OTHER
Intervention: No intervention will be used.
Description: Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
Study: NCT04806139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Enhance Fitness
Description: The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
Study: NCT05112926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
Study: NCT06593249

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention, observational study

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention, observational study
Study: NCT06613100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: Intravenous (IV) infusion
Study: NCT05672472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: Continuous infusion of sivelestat sodium for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sivelestat sodium
Description: Continuous infusion of sivelestat sodium for 5 days
Study: NCT06095505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets
Study: NCT06718452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT 1 sachet
Description: 1 dose day to be absorbed sublingually

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT 2 sachet day
Description: 1 sachet two times a day to be sublingually absorbed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration of PEA-LUT
Study: NCT06725121

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Atezolizumab & Bevacizumab
Description: Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.

Intervention type: DRUG
Group type: OTHER
Intervention: Yttrium-90 (Y-90)
Description: Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
Study: NCT06734065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReDS-guided heart failure management program
Description: Remote dielectric sensing (ReDS) system (Sensible Medical Innovations Ltd., Netanya, Israel) is a novel electromagnetic energy-based technology that accurately quantifies changes in lung fluid concentration non-invasively.~Patients in the intervention group will receive a three-month, ReDS-guided heart failure management program in addition to usual care.~The program, led by nurses, will integrate algorithms for diuretic use, a structured follow-up schedule, and self-care support tailored to pulmonary fluid levels assessed by ReDS.
Study: NCT05503862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YoSperm
Description: The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
Study: NCT06734273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mounjaro
Description: In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy
Description: Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
Study: NCT06735105

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scanning parameter
Description: Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scanning parameter
Description: Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.
Study: NCT06734546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
Study: NCT05168124

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance Commitment Therapy for chronic fatigue
Description: ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Micro breaks in everyday life for chronic fatigue
Description: In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being.